Hans van Houte
2021
In 2021, Hans van Houte earned a total compensation of $1.7M as Chief Financial Officer at Nurix Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $175,130 |
|---|---|
| Option Awards | $1,053,065 |
| Salary | $413,750 |
| Other | $18,012 |
| Total | $1,659,957 |
van Houte received $1.1M in option awards, accounting for 63% of the total pay in 2021.
van Houte also received $175.1K in non-equity incentive plan, $413.8K in salary and $18K in other compensation.
Rankings
In 2021, Hans van Houte's compensation ranked 6,810th out of 12,406 executives tracked by ExecPay. In other words, van Houte earned more than 45.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,810 out of 12,406 | 45th |
Division Manufacturing | 2,960 out of 5,494 | 46th |
Major group Chemicals And Allied Products | 1,312 out of 2,369 | 45th |
Industry group Drugs | 1,170 out of 2,090 | 44th |
Industry Pharmaceutical Preparations | 852 out of 1,537 | 45th |
Source: SEC filing on March 25, 2022.
van Houte's colleagues
We found four more compensation records of executives who worked with Hans van Houte at Nurix Therapeutics in 2021.